With the acquisition of surgical technology company Visualase, Medtronic is further bolstering one of its own fastest growing segments--as well as a large and fast growing group for Covidien. Medtronic expects to complete its $42.9 billion acquisition of Covidien by early 2015.
Medtronic is teaming up with LifeTech Scientific to manufacture and distribute cardiac devices for China's growing cardiovascular market.
The Medtronic merger with Covidien could offer a particular threat to C.R. Bard's vascular business--its largest segment and one of its fastest growing. The company was clear that it's actively in the market for its own strategic acquisitions; it hasn't disclosed a sizeable deal in almost a year.
Miss Idaho is trending, but it has nothing to do with pageantry. The hashtag "show me your pump" became popular after newly crowned Sierra Sandison, diagnosed with Type I diabetes in 2012, was spotted on stage with her insulin pump by her side.
The Obama administration is cracking down on companies moving operations overseas for tax-inversion purposes, a move that could hold negative implications for Medtronic in its $43 billion proposed deal with Covidien.
Tasked several years ago with forming a team to develop Medtronic's prototype Hospital of the Future, Director of IT Innovation Paul Thompson likened the process to the biology of birth--of an elephant, not salmon.
As Covidien strides into a merger with Medtronic, the company last week announced the appointment of Bill Burke as CFO for Covidien Europe.
Insulin pumps do a better job of helping control glucose levels in people with Type 2 diabetes than multiple daily injections, according to results from a new study funded by medical device maker Medtronic.
The president of Covidien's $1.6 billion vascular product group said that the impending merger with Medtronic was necessary from her perspective because being "a vascular player without cardiovascular, I think long term that would have been a real issue.
With more M&A, product development and restructuring on the horizon, med tech CEOs have their work cut out for them in the coming year. But for now, here's the breakdown of what they took home in 2013.